<DOC>
	<DOCNO>NCT00404157</DOCNO>
	<brief_summary>This Phase III , multicenter , extension study evaluate safety rituximab administer scheduled basis approximately every 6 month . All subject complete Week 52 visit Study U2970g eligible study , long inclusion exclusion criterion meet .</brief_summary>
	<brief_title>A Study Evaluate Safety Rituximab Retreatment Subjects With Lupus Nephritis Previously Enrolled Study U2970g</brief_title>
	<detailed_description />
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Ability willingness provide write informed consent comply requirement study protocol Participation Study U2970g completion Week 52 visit study For subject reproductive potential ( male female ) , use reliable mean contraception throughout study participation Discontinuation withdrawal Study U2970g failure complete Week 52 visit Any safety concern potentially attributable rituximab investigator 's opinion may jeopardize subject safety In investigator 's opinion , lack clinical improvement Week 52 Study U2970g propose therapy would represent risk without benefit Current thrombocytopenia high risk develop clinically significant bleed organ dysfunction require therapy plasmapheresis acute blood platelet transfusion Lack peripheral venous access Pregnancy lactation History severe , allergic , anaphylactic reaction humanize murine monoclonal antibody Significant new uncontrolled disease organ system relate SLE ( e.g. , poorly control chronic obstructive pulmonary disease asthma , cardiovascular disease , accelerate hypertension , major depression ) investigator 's opinion would preclude subject participation Known active infection kind ( exclude fungal infection nail bed ) , major episode infection require hospitalization , treatment IV antibiotic within 4 week study drug infusion oral antibiotic within 2 week study drug infusion History cancer , include solid tumor , hematologic malignancy , carcinoma situ Major surgery within 4 week prior screen Intolerance contraindication oral IV corticosteroid Lipase &gt; 2 x upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2.5 x ULN Amylase level &gt; 2 x ULN Absolute neutrophil count &lt; 1.5 x 10^3/uL History positive hepatitis B surface antigen hepatitis C serology Hemoglobin &lt; 7 g/dL unless cause autoimmune hemolytic anemia result SLE Platelet count &lt; 10,000/uL Receipt live vaccine within 28 day prior treatment</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Lupus</keyword>
	<keyword>U2970g</keyword>
</DOC>